Schedule - search results

If you're not happy with the results, please do another search

0 365

Terra Tech Corp. Schedules First Quarter 2017 Earnings Release for Thursday, May 11, 2017

The company will also host a conference call on Thursday, May 11, 2017 at 9:00 AM Eastern.

Dial-In Number: 1-857-232-0157

Access Code: 422095

Derek Peterson, Chairman and CEO of Terra Tech Corp., will be answering shareholder questions at the end of the call. Should you have questions during or prior to the conference call please send an email to with TRTC Question in the subject line. Mr. Peterson will answer as many questions as time will allow.

For those unable to participate in the live conference call, a replay will be available at An archived version of the webcast will also be available on the investor relations section of the company’s website.

To be added to the Terra Tech email distribution list, please email with TRTC in the subject line.

About Terra Tech

Terra Tech Corp. (TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, MediFarm LLC and GrowOp Technology. Blüm’s retail medical cannabis facilities focus on providing the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions. Blüm offers a broad selection of medical cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces medical cannabis-extracted products for regulated medical cannabis dispensaries throughout California. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania and the Midwest. Terra Tech’s MediFarm LLC subsidiaries are focused on medical cannabis cultivation and permitting businesses throughout Nevada. The Company’s wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies.

For more information about Terra Tech Corp visit:
For more information about IVXX visit:
For more information about Blüm Nevada visit:
For more information about Blüm Oakland visit:
Visit us on Facebook @
Follow us on Twitter @terratechcorp
For more information about Edible Garden visit:
Visit Edible Garden on Facebook @
Visit IVXX on Facebook @

0 1603

Matt Gaetz is a 34-year-old attorney who, while in the Florida legislature, pushed for accelerated executions and blocked any revision of the stand-your-ground law following Trayvon Martin’s shooting death. He now represents most of the Florida Panhandle in Congress. Most of us would call those solid conservative bona fides “textbook reactionary,” but back at home in Gaetz’s First Congressional District, they’re local mores. His district is so solidly Republican, it’s an island of dark red floating in a less-red sea.

The district is the most conservative in Florida, with a plus-22 conservative rating from the Cook Partisan Voting Index; which may be off by double-digits. In November’s election, Gaetz defeated the Democratic challenger by nearly 40% points. So far in Congress, Gaetz has made waves for introducing a bill that would permanently abolish the Environmental Protection Agency. And in February, during the buildup leading to the failure to repeal or replace Obamacare, Gaetz ended a town-hall meeting by leading a chant to “Make America Great Again!”

Gaetz, then, is the perfect person to carry what could be the single most important marijuana-related reform bill in a session of Congress full of cannabis-related legislation.
On April 6, Gaetz and fellow Florida Rep. Darren Soto, (D-Orlando) introduced a bill that, if passed, would force Attorney General Jeff Sessions to remove marijuana from Schedule I of the Controlled Substances Act to Schedule III. Because, you see, even if Floridians want to shoot people and then put shooters on an accelerated death-row conveyor belt, they want to use medical marijuana while doing it. On the same day Donald Trump and Matt Gaetz were elected, Florida voters also overwhelmingly voted in favor of expanded medical cannabis access.

Gaetz stated, “This drug should not be in the same category as heroin and LSD, and we do not need to continue with a policy that turns thousands of young people into felons every year. Nor do we need to punish the millions of people who are sick and seeking medical help from pain, from muscle wasting, from chemotherapy-induced nausea.” Rescheduling is a slightly different tactic than outright legalization. Some marijuana hardliners want “descheduling,” rendering cannabis no more controlled than a tomato (as long as it’s not an invasive species of tomato), but Gaetz’s tactic is both more effective and more realistic. It also goes further than some prior efforts, led by Democrats.

0 11193

The most recent proposal for marijuana before Congress would place the drug as a Schedule III substance, a classification shared by Tylenol with codeine, ketamine, and dronabinol. Two Florida congressmen, Republican Representative Matt Gaetz and Democratic Representative Darren Soto, introduced legislation that would transfer marijuana to Schedule III of the Controlled Substances Act from its current standing as a Schedule I substance, the strictest of the classifications.

Having marijuana on a lower scale would uphold the rights of states that have legalized the the use of it medically, allow for banking activities, and create a clearer path for research, Gaetz stated, “I have supported cannabis reform as a state legislator, and I want to see the people that I fought for in my state have access to a legal, high-quality product that’s been well-researched.”

When Gaetz was a state legislator in 2014 and 2015, he backed legislation to legalize “non-euphoric” marijuana for medical use and a proposal to allow terminally ill patients to access full-strength, non-smokeable cannabis. Both were signed into law. Prior to those efforts, Gaetz stood in opposition to medical marijuana proposals. What changed, he said, was watching Doctor Sanjay Gupta’s CNN special report, “Weed,” which chronicled the stories of medical marijuana patients and the challenges of medical research.

After watching the series, Gaetz said he thought that “somebody should do something about that.” He stated, “Until, I realized I could do that.” If successful, the yet-to-be-named House Bill 2020 would not affect recreational marijuana businesses in operation. Gaetz said The legislation is aimed at bolstering research and creating an economic boost by allowing medical marijuana dispensaries to bank openly. He said, “It’s a modest step forward to try to find the most possible common ground. I’ve seen that work.”

Marijuana’s Schedule I status has resulted in limitations for research. Federally approved studies have to utilize a marijuana study drug grown by University of Mississippi, the only federally approved cultivator. Researchers have long argued that the study the does not accurately represent the potency and strains available to consumers in dispensaries. In August, the Drug Enforcement Administration announced it would allow privately operated cultivators to apply to grow marijuana for research, and several companies have started the application process.

0 1005

DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug

Insys Therapeutics, Inc. (INSY) (“Insys” or the “Company”) today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.

On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros.

Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer, stated, “Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia associated weight loss, respectively.”

“We look forward to interacting with the FDA to finalize the labeling and subsequent launch of Syndros in the second half of 2017,” concluded Vetticaden.

Important Safety Information

Syndros is a cannabinoid indicated in adults for the treatment of:

  • Anorexia associated with weight loss in patients with AIDS, and
  • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

The use of dronabinol may cause psychiatric and cognitive effects and impair mental and/or physical abilities.
Patients with cardiac disorders may experience hypotension, hypertension, syncope or tachycardia.
May cause disulfiram-like reaction.
Weigh the potential risk versus benefits before prescribing Syndros to patients with a history of seizures, including those requiring anti-epileptic medication or other factors that lower the seizure threshold.
Assess risk for abuse or misuse in patients with a history of substance abuse or dependence, prior to prescribing Syndros and monitor for the development of associated behaviors or conditions.
Consider dose reduction or discontinuation, if worsening of symptoms while on treatment.
The safety and effectiveness of Syndros have not been established in pediatric patients.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.

SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding (i) the anticipated scheduling and launch of SYNDROS™, (ii) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (iii) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law.

0 489

Zoned Properties Schedules Conference Call to Report 2016 Fourth Quarter and Year End Financial Results

Zoned Properties, Inc. (OTCQX: ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed marijuana industry, today announced it will release financial results for its 2016 fourth quarter and year end on March 20, 2017.

The Company will hold a conference call at 4:30 p.m. Eastern (U.S.) time on March 20, 2017. To participate in the live conference call, please dial 1-866-682-6100 five to 10 minutes prior to the scheduled conference call time. International callers should dial 1-862-255-5401. Please reference Zoned Properties.

A replay will be available until April 3, 2017. To access the replay, dial 1-877-481-4010 or 1-919-882-2331. When prompted, enter Conference Passcode 10245.

The call will also be available live by webcast over the Internet and accessible at:

About Zoned Properties, Inc. (ZDPY):

Zoned Properties is a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries. The Company acquires commercial properties that face unique zoning challenges and identifies solutions that can potentially have a major impact on the cash flow and value generated. Zoned Properties targets commercial properties that can be acquired and potentially re-zoned for specific purposes. Zoned Properties does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substances Act.

0 1043

MassRoots Schedules Conference Call on February 13, 2017

MassRoots, Inc. (MSRT), one of the leading technology platforms for the cannabis industry, announced today that the Company will host a shareholder update call on Monday, February 13, 2017 at 4:15 pm EST.  During the call, management will provide insight on recent and upcoming developments at the Company and within the evolving cannabis marketplace.

In order to participate in the conference call, please dial (toll free) (877) 407-8293. Please use conference pass code 13655333. For international callers, please dial (201) 689-8349.

An audio replay of the conference call will be available in the investor relations section of the Company’s website following completion of the call for approximately 2 weeks.  To listen to the replay, please dial (toll free) (877) 660-6853 or (international) (201) 612-7415.

About MassRoots
MassRoots is one of the largest technology platforms for the regulated cannabis industry. The Company’s mobile apps enable consumers to make educated cannabis purchasing decisions through community-drive reviews. MassRoots is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. For more information, please visit

Forward-looking Statements
Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots’ business, potential partnerships, new features, and related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Factors or events that could cause our actual results to differ may emerge from time to time. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements.

0 816

Before the federal judge in New York could decide whether or not the classification of pot as a Schedule I drug under the Controlled Substances Act is a civil rights violation; the defendant charged in the case accepted a two-year prison term. The public defenders appointed to represent 58-year-old Randy Wade Kenyon following possession charges of more than 800 marijuana plants, filed a motion with the court stating the DEA’s Schedule I listing for cannabis violated Kenyon’s civil rights; as per the Bradford Era. The motion states this classification indicates the herb has “no medicinal value,” but according to state law, it clearly does.

“Especially irrational, however, is the government’s insistence that marijuana has no ‘currently accepted’ medical use,” the motion declared. “Such a position is simply unsustainable as demonstrated by numerous peer-reviewed studies, the recent passage of regulations by the New York Department of Health governing its medicinal use, the recent publication of an article in the Journal of American Medical Association noting marijuana’s efficacy compared to opioids and its widespread prescribed use of marijuana in states that have permitted the medicinal use of marijuana.”

Many of Kenyon’s illegal cultivation operations in Cattaraugus and Allegany counties were raided by a statewide weed eradication effort funded by the DEA In August. This caused Kenyon to be charged with a felony under federal law; putting him at risk of being sentenced up to 40 years in prison and fines reaching $500,000.

Even though medical cannabis is legal in New York, only companies with commercial licenses are permitted to cultivate it. As opposed to other legal states, NY patients are not permitted to grow weed at home; especially when hundreds of plants are concerned. Because of this the DEA keeps giving law enforcement agencies all over the state hundreds of thousands of dollars yearly “specifically” to track down illegal growing sites.

New York received $356,000 to cut down more than 11,000 marijuana plants, leading to the seizure of more than $1.6 million in assets, In 2015. Unfortunately, a plea agreement was accepted before the federal judge was forced to address the civil rights argument in Kenyon’s case. Kenyon will now live in a federal prison for the next couple of years. Ironically, no one has ever successfully argued the civil rights defense in connection to a federal cannabis crime. In fact, the Supreme Court has yet to even acknowledge the medical necessity defense.

0 1243

The American Legion wants the United States government to get serious, once and for all, about removing the cannabis plant from the restrictions of its classifying marijuana as Schedule I narcotic. This past week, the Legion passed a resolution at its yearly convention aimed at convincing congressional leaders to reschedule marijuana to a classification that will bring about more research opportunities.

The purpose of this newfound order is to get the federal government to reconsider lifting some of the restrictions that have long since stopped marijuana from being acknowledged as medicine for those soldiers suffering from post-traumatic stress disorder and traumatic brain issues. Her speech is largely recognized for getting the American Legion to support the cannabis cause.

“I only heard very positive feedback from the thousands of veterans in the audience,” Sisley told

“I was stunned at how little controversy there was. It seems highly unanimous among American Legion members that we owe it to the veteran community to demand an end to the barriers to this kind of cannabis research.” The American Legion’s position on medical marijuana comes just one month after the DEA announced that it will not remove the cannabis plant from its current Schedule I classification.

Its conclusion, according to acting DEA administrator Chuck Rosenberg, was done because the FDA has yet to justify if marijuana is “Safe and effective medicine.” Yet, a number of military veterans say it is the most effective medicine.

In a recent report from Stars & Stripes, Roberto Pickering, an infantry Marine who fought in the 2003 invasion of Iraq say’s marijuana saved his life because it stopped him from depending on a mixture of dangerous prescription drugs to deal with PTSD. “This war doesn’t end when you come back,” Pickering said.

Marijuana “Really improved my quality of life I found what works for me.”

1 1149

Although the marijuana community has been waiting for pretty much the whole summer for the DEA to announce that it was finally using its power for a positive use by rescheduling the classification of the cannabis plant to a ranking less threatening to the grand scheme of public health and safety, a recent report from NPR shows that the federal government’s anti-drug henchman have come to the decision to further defend marijuana as a substance that is just as dangerous as heroin.

This past Wednesday, reports began to come to light that the DEA was preparing to announce its long-awaited rescheduling decision for marijuana. The agency gave a story to the New York Times that implied that its decision had nothing to do with the fabled reschedule, though a separate problem altogether that was intended to allow more universities to get into the business of growing cannabis for investigative study purposes.

The Times’ report went on to say that while the DEA was throwing out the idea of removing pot from its list of the most dangerous drugs in the world, “This week, the agency did not take such a step.” However come to find out that was all just a big misunderstanding, as a report from the people at NPR would soon show a discussion with acting DEA administrator Chuck Rosenberg, who told the news source that the agency had turned down the rescheduling requests submitted by a couple of Democratic governors because the federal government was unable to clarify if marijuana did present some therapeutic benefit when used.

It seems that the recommendation provided last year by the U.S. Food and Drug Administration was that cannabis has “No currently accepted medical use in treatment in the United States.” Interestingly, Rosenberg wants the cannabis community to know that the DEA’s decision to continue labeling marijuana as one of the most harmful substances known to man has nothing to do with the fact that cannabis has never contributed to the death of a single person.

“This decision isn’t based on danger,” he told NPR. “This decision is based on whether marijuana, as determined by the FDA, is a safe and effective medicine and it’s not.” There was apparently a letter fired off to the lawmakers who petitioned the federal drug agency for the rescheduling that said, “Evaluating the safety and effectiveness of drugs is a highly specialized endeavor,” and that the opinions of doctors all across the nation carried no weight in the decision to continue classifying marijuana a Schedule I drug under the Controlled Substances Act.

What appears to be true is that the DEA is gearing up to officially announce that it will expand the amount of federally regulated cannabis to be grown in the United States for research purposes beyond the grips of the University of Mississippi. Although it is not known exactly which universities old Uncle Sam plans to let into his pot cultivation game, there does not appear to be any limits on the number of potential cultivators that could qualify under the updated policy. Many researchers have complained in the past that the University of Mississippi’s monopoly on federal pot cultivation was preventing them from accomplishing any real work.

“If you were a researcher who thought a product with high THC would help someone with a painful cancer, you were out of luck,” John Hudak, a senior fellow at the Brooking Institution, explained to the Times.

“You couldn’t access high THC marijuana in the same way you could buy it [legally] in a market in Colorado,” Rosenberg told NPR that as long as all of the new policies dealing with marijuana research is carried out in a suitable fashion, the agency might one day reconsider its decision to reschedule the cannabis plant.

“A clear and growing majority of American voters support legalizing marijuana outright and the very least our representatives should do is let states implement their own policies, unencumbered by an outdated ‘Reefer Madness’ mentality that some in law enforcement still choose to cling to.

” As it stands, the only hope for a less restrictive national marijuana policy is for the DEA and FDA to come to terms on whether cannabis is medicine or for Congressional leaders and the President of the United States to stop pussyfooting around and pass legislation that liberates the leaf once and for all.

Not much is changing with respect to the cannabis plant.

0 930

One of the most anticipated political moves this year has been the Drug Enforcement Administration deciding whether or not they would like to reschedule marijuana. It has been widely anticipated that they were going to during the first half of 2016, as they had originally reported. There was then an announcement that the Drug Enforcement Administration was going to release their decision on August 1st, as per an “anonymous DEA lawyer.” Well, the first half of 2016 has certainly passed, and so has August 1st. There is no word from the DEA that they would like to reschedule marijuana or when the announcement will come.

It’s informally official. A senior official at the Drug Enforcement Administration has affirmed that the DEA won’t reschedule pot in 2016, says a lawyer who talked with him before the end of last week. “The DEA is not going to reschedule marijuana this year…. They aren’t issuing a public announcement about the change,” the attorney stated.

Numerous pot advocates — and the officials who bolster them — have been trusting that the DEA would reschedule weed from a Schedule I to a Schedule II substance. The renaming would recognize that the medication holds restorative properties and make it possible to conduct more research. As was widely reported a month ago, the DEA had sent a letter to administrators in April, saying that the office would discharge a declaration on rescheduling in the principal half of this current year. In any case, July 1st went back and forth with no declaration, and the DEA has declined to set another course of events.

“We do not have a date set to make an announcement about that one way or another,” a representative in the DEA’s public affairs office added.

And even if they did have a date set, it likely would not be during 2016.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
Ad Placements